New Results
Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15
Tyler Faust, Hojong Yoon, Radosław P. Nowak, Katherine A. Donovan, Zhengnian Li, Quan Cai, Nicholas A. Eleuteri, Tinghu Zhang, Nathanael S. Gray, View ORCID ProfileEric S. Fischer
doi: https://doi.org/10.1101/738534
Tyler Faust
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Hojong Yoon
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Radosław P. Nowak
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Katherine A. Donovan
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Zhengnian Li
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Quan Cai
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Nicholas A. Eleuteri
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Tinghu Zhang
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Nathanael S. Gray
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Eric S. Fischer
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Posted August 16, 2019.
Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15
Tyler Faust, Hojong Yoon, Radosław P. Nowak, Katherine A. Donovan, Zhengnian Li, Quan Cai, Nicholas A. Eleuteri, Tinghu Zhang, Nathanael S. Gray, Eric S. Fischer
bioRxiv 738534; doi: https://doi.org/10.1101/738534
Subject Area
Subject Areas
- Biochemistry (11753)
- Bioengineering (8754)
- Bioinformatics (29205)
- Biophysics (14975)
- Cancer Biology (12102)
- Cell Biology (17414)
- Clinical Trials (138)
- Developmental Biology (9423)
- Ecology (14185)
- Epidemiology (2067)
- Evolutionary Biology (18309)
- Genetics (12246)
- Genomics (16805)
- Immunology (11870)
- Microbiology (28098)
- Molecular Biology (11598)
- Neuroscience (60979)
- Paleontology (452)
- Pathology (1871)
- Pharmacology and Toxicology (3238)
- Physiology (4960)
- Plant Biology (10427)
- Synthetic Biology (2886)
- Systems Biology (7341)
- Zoology (1651)